Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00519792 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
A Phase 1 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00519792 is a Phase 1 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT00519792, a Phase 1 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Omega DUROS® is an implantable drug delivery system designed to deliver omega interferon subcutaneously at a constant rate for 90 days. This study is being performed to evaluate the safety and antiviral effects of omega interferon delivered by the Omega DUROS® device in combination with ribavirin in subjects with chronic Hepatitis C genotype 1.
Interventions
- DRUG Omega DUROS device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00519792
The ClinicalTrials.gov registry entry for NCT00519792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Omega DUROS device is the first listed.
NCT00519792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00519792 about?
NCT00519792 is a clinical study titled "Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment". Omega DUROS® is an implantable drug delivery system designed to deliver omega interferon subcutaneously at a constant rate for 90 days. This study is being performed to evaluate the safety and antiviral effects of omega interferon delivered by the Omega DUROS® device in combination with ribavirin i...
What is the current status of trial NCT00519792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00519792?
The interventions under investigation include: Omega DUROS device (DRUG).
Who is sponsoring clinical trial NCT00519792?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.